-

02:43:59 AM

VOR Stock News

VOR - Vor Biopharma Inc

01/19/23 8:00 AM

Nasdaq : VOR

conferencesclinical triallow float

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33)

RHEA-AI

neutral

01/12/23 8:00 AM

Nasdaq : VOR

conferenceslow float

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual Oncology Conference –

RHEA-AI

neutral

12/07/22 7:45 AM

Nasdaq : VOR

offeringlow float

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwritten

RHEA-AI

neutral

12/07/22 7:30 AM

Nasdaq : VOR

low float

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Vor Bio (Nasdaq: VOR),

RHEA-AI

neutral

11/22/22 8:00 AM

Nasdaq : VOR

conferenceslow float

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conference Presentation: Tuesday, November

RHEA-AI

neutral

11/10/22 4:15 PM

Nasdaq : VOR

earningslow float

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome

RHEA-AI

neutral

11/01/22 8:00 AM

Nasdaq : VOR

conferenceslow float

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Credit Suisse 31st Annual Healthcare Conference A virtual presentation will be

RHEA-AI

neutral

10/12/22 8:00 AM

Nasdaq : VOR

managementlow float

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience to

RHEA-AI

very positive

10/11/22 8:00 AM

Nasdaq : VOR

low float

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Annual Congress CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE

RHEA-AI

neutral

09/28/22 8:00 AM

Nasdaq : VOR

low float

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Vor Bio (Nasdaq: VOR), a clinical-stage cell and

RHEA-AI

very positive